Equities

Haleon PLC

HLN:LSE

Haleon PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)380.30
  • Today's Change7.90 / 2.12%
  • Shares traded12.08m
  • 1 Year change15.84%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 16:52 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform5
Hold6
Sell1
Strong Sell0

Share price forecast

The 15 analysts offering 12 month price targets for Haleon PLC have a median target of 400.00, with a high estimate of 456.00 and a low estimate of 340.00. The median estimate represents a 5.18% increase from the last price of 380.30.
High19.9%456.00
Med5.2%400.00
Low-10.6%340.00

Dividends

In 2023, Haleon PLC reported a dividend of 0.06 GBP, which represents a 150.00% increase over last year. The 18 analysts covering the company expect dividends of 0.06 GBP for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)150.00%
More ▼

Earnings history & estimates

On Oct 31, 2024, Haleon PLC reported 3rd quarter 2024 earnings of 4.58 per share. This result was in line with the consensus of the 2 analysts following the company and under-performed last year's 3rd quarter results by 8.80%.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate+4.18%
Haleon PLC reported annual 2023 earnings of 17.30 per share on Feb 29, 2024.
Average growth rate-5.98%
More ▼

Revenue history & estimates

Haleon PLC had 3rd quarter 2024 revenues of 2.78bn. This missed the 2.85bn consensus estimate of the 3 analysts following the company. This was 6.90% below the prior year's 3rd quarter results.
Average growth rate-0.09%
Haleon PLC had revenues for the full year 2023 of 11.30bn. This was 4.09% above the prior year's results.
Average growth rate+4.09%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.